94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
REVIEW article
Front. Cell Dev. Biol.
Sec. Stem Cell Research
Volume 13 - 2025 | doi: 10.3389/fcell.2025.1593207
This article is part of the Research TopicAdvancements in Molecular and Cellular Mechanisms of Stem Cells in Tissue Development and RegenerationView all 7 articles
A comprehensive analysis of induced pluripotent stem cell (iPSC) production and applications
Provisionally accepted
Margarita Matiukhova
Anastasia Ryapolova
Vladimir Andriianov
Vasiliy ReshetnikovSophia Zhuravleva
Roman Ivanov
Karabelsky Alexander
Ekaterina Minskaia*- Sirius University, Sochi, Russia
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
The ability to reprogram mature, differentiated cells into induced pluripotent stem cells (iPSCs) using exogenous pluripotency factors opened up unprecedented opportunities for their application in biomedicine. iPSCs are already successfully used in cell and regenerative therapy, as various drug discovery platforms and for in vitro disease modeling. However, even though already 20 years have passed since their discovery, the production of iPSC-based therapies is still associated with a number of hurdles due to low reprogramming efficiency, the complexity of accurate characterization of the resulting colonies, and the concerns associated with the safety of this approach. However, significant progress in many areas of molecular biology facilitated the production, characterization, and thorough assessment of the safety profile of iPSCs. The number of iPSC-based studies has been steadily increasing in recent years, leading to the accumulation of significant knowledge in this area. In this review, we aimed to provide a comprehensive analysis of methods used for reprogramming and subsequent characterization of iPSCs, discussed barriers towards achieving these goals, and various approaches to improve the efficiency of reprogramming of different cell populations. In addition, we focused on the analysis of iPSC application in preclinical and clinical studies. The accumulated breadth of data helps to draw conclusions about the future of this technology in biomedicine.
Keywords: induced pluripotent stem cells1, iPSC2, Transcription Factors3, cell reprogramming4, cell therapy5, regenerative medicine6, in vitro disease modeling7, viral delivery8
Received: 13 Mar 2025; Accepted: 14 Apr 2025.
Copyright: © 2025 Matiukhova, Ryapolova, Andriianov, Reshetnikov, Zhuravleva, Ivanov, Alexander and Minskaia. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Ekaterina Minskaia, Sirius University, Sochi, Russia
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.